Association of human papillomavirus with Fanconi anemia promotes carcinogenesis in Fanconi anemia patients

Reviews in Medical Virology

Volumn 25, Issue 6, 2015, Pages 345-353

  Liu, Guang Bin ^a   Chen, Jiezhong ^b,c   Wu, Zhan He ^d   Zhao, Kong Nan ^b,e  

^a UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN E6; PROTEIN E7; PROTEIN KINASE B; PROTEIN P53; PROTEIN P63; RETINOBLASTOMA PROTEIN; ONCOPROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE CHECKPOINT; CELL HYPERPLASIA; CELL PROLIFERATION; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; GENE AMPLIFICATION; GENOMIC INSTABILITY; HUMAN; IMMUNE SYSTEM; MOLECULAR PATHOLOGY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; VIRUS GENOME; CARCINOMA, SQUAMOUS CELL; COMPLICATION; HEAD AND NECK NEOPLASMS; HOST PATHOGEN INTERACTION; METABOLISM; PAPILLOMAVIRIDAE; PHYSIOLOGY;

CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; FANCONI ANEMIA; HEAD AND NECK NEOPLASMS; HOST-PATHOGEN INTERACTIONS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84947428719     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1834     Document Type: Review

References (85)

1. Kee Y, D'Andrea AD. Molecular pathogenesis and clinical management of Fanconi anemia. The Journal of Clinical Investigation 2012; 122(11): 3799.
2. Pickering A, Zhang J, Panneerselvam J, Fei P. Advances in the understanding of the Fanconi anemia tumor suppressor pathway. Cancer Biology and Therapy 2013; 14(12): 1089-1091.
3. Hoskins EE, Morreale RJ, Werner SP. Fanconi anemia deficiency stimulates HPV-associated hyperplastic growth in organotypic epithelial raft culture. Oncogene 2009; 28(5): 674-685.
4. Moldovan GL, D'Andrea AD. How the Fanconi anemia pathway guards the genome. Annual Review of Genetics 2009; 43: 223-249.
5. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annual Review of Genetics 2011; 45: 247-271.
6. Alter BP, Giri N, Savage SA, Quint WG, de Koning MN, Schiffman M. Squamous cell carcinomas in patients with Fanconi anemia and dyskeratosis congenita: a search for human papillomavirus. International Journal of Cancer 2013; 133(6): 1513-1515.
7. Kutler DI, Auerbach AD, Satagopan J. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Archives of Otolaryngology - Head and Neck Surgery 2003; 129(1): 106-112.
8. van Zeeburg HJ, Snijders PJ, Joenje H, Brakenhoff RH. Re: human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. Journal of the National Cancer Institute 2004; 96(12): 968; author reply 968-969.
9. Kutler DI, Wreesmann VB, Goberdhan A. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. Journal of the National Cancer Institute 2003; 95(22): 1718-1721.
10. Park JW, Shin MK, Lambert PF. High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA damage response, an activity mediated by E7's inactivation of pocket proteins. Oncogene 2014; 33(26): 3383-3391.
11. Guan P, Howell-Jones R, Li N. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. International Journal of Cancer 2012; 131(10): 2349-2359.
12. Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. Journal of Infection and Chemotherapy 2012; 18(6): 807-815.
13. Stanley MA, Pett MR, Coleman N. HPV: from infection to cancer. Biochemical Society Transactions 2007; 35(Pt 6): 1456-1460.
14. Zhao KN, Chen J. Codon usage roles in human papillomavirus. Reviews in Medical Virology 2011; 21(6): 397-411.
15. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002; 2(5): 342-350.
16. Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes. Journal of General Virology 2013; 94(Pt 11): 2504-2514.
17. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. The Lancet 2007; 370(9590): 890-907.
18. Bosch F, Lorincz A, Munoz N, Meijer C, Shah K. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002; 55(4): 244-265.
19. Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecologic Oncology 2007; 107(2 Suppl 1): S2-S5.
20. Johansson C, Schwartz S. Regulation of human papillomavirus gene expression by splicing and polyadenylation. Nature Reviews. Microbiology 2013; 11(4): 239-251.
21. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010; 401(1): 70-79.
22. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Research 2002; 89(2): 213-228.
23. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. Journal of Virology 1991; 65(1): 473-478.
24. Liao S, Deng D, Zhang W. Human papillomavirus 16/18 E5 promotes cervical cancer cell proliferation, migration and invasion in vitro and accelerates tumor growth in vivo. Oncology Reports 2013; 29(1): 95-102.
25. Ghittoni R, Accardi R, Hasan U, Gheit T, Sylla B, Tommasino M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010; 40(1): 1-13.
26. Duensing S, Münger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. International Journal of Cancer 2004; 109(2): 157-162.
27. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nature Reviews Molecular Cell Biology 2010; 11(3): 220-228.
28. Thomas LK, Bermejo JL, Vinokurova S, Lambert PF. Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract-a systematic review and meta-analysis. European Journal of Cancer 2014; 50(1): 85-98.
29. Lowy DR, Gillison ML. A new link between Fanconi anemia and human papillomavirus-associated malignancies. Journal of the National Cancer Institute 2003; 95(22): 1648-1650.
30. Carvalho JP, Dias ML, Carvalho FM, Del Pilar Estevez Diz M, Petito JW. Squamous cell vulvar carcinoma associated with Fanconi's anemia: a case report. International Journal of Gynecological Cancer 2002; 12(2): 220-222.
31. Gillespie MB, Rubinchik S, Hoel B, Sutkowski N. Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. Current Treatment Options in Oncology 2009; 10(5-6): 296-307.
32. Gillison ML, Koch WM, Capone RB. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute 2000; 92(9): 709-720.
33. Alter BP, Giri N, Pan Y, Savage SA, Pinto LA. Antibody response to human papillomavirus vaccine in subjects with inherited bone marrow failure syndromes. Vaccine 2014; 32(10): 1169-1173.
34. Socie G, Scieux C, Gluckman E. Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantation 1998; 66(5): 667-670.
35. Gulbahce N, Yan H, Dricot A. Viral perturbations of host networks reflect disease etiology. PLoS Computational Biology 2012; 8(6): e1002531.
36. Park JW, Pitot HC, Strati K. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer. Cancer Research 2010; 70(23): 9959-9968.
37. Uziel O, Reshef H, Ravid A. Oxidative stress causes telomere damage in Fanconi anaemia cells-a possible predisposition for malignant transformation. British Journal of Haematology 2008; 142(1): 82-93.
38. Pipaon C, Real PJ, Fernandez-Luna JL. Defective binding of transcriptional repressor ZEB via DNA methylation contributes to increased constitutive levels of p73 in Fanconi anemia cells. FEBS Letters 2005; 579(21): 4610-4614.
39. Wang L, Romero M, Ratajczak P. Increased apoptosis is linked to severe acute GVHD in patients with Fanconi anemia. Bone Marrow Transplantation 2013; 48(6): 849-853.
40. Santegoets LA, van Baars R, Terlon A. Different DNA damage and cell cycle checkpoint control in low- and high-risk human papillomavirus infections of the vulva. International Journal of Cancer 2012; 130(12): 2874-2885.
41. Valeri A, Alonso-Ferrero ME, Rio P. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells. PLoS One 2010; 5(12): e15525.
42. Cherubini G, Naim V, Caruso P. The FANC pathway is activated by adenovirus infection and promotes viral replication-dependent recombination. Nucleic Acids Research 2011; 39(13): 5459-5473.
43. Chen X, Wilson JB, McChesney P. The Fanconi anemia proteins FANCD2 and FANCJ interact and regulate each other's chromatin localization. Journal of Biological Chemistry 2014; 289(37): 25774-25782.
44. Freie BW, Ciccone SL, Li X. A role for the Fanconi anemia C protein in maintaining the DNA damage-induced G2 checkpoint. Journal of Biological Chemistry 2004; 279(49): 50986-50993.
45. Martinez A, Hinz JM, Gomez L. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutation Research 2008; 656(1-2): 1-7.
46. Wang SS, Bratti MC, Rodriguez AC. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. Journal of Infectious Diseases 2009; 199(1): 20-30.
47. Koshiol J, Hildesheim A, Gonzalez P. Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited. Cancer Epidemiology, Biomarkers and Prevention 2009; 18(5): 1631-1637.
48. Collis SJ, Ciccia A, Deans AJ. FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex. Molecular Cell 2008; 32(3): 313-324.
49. Niedzwiedz W, Mosedale G, Johnson M. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Molecular Cell 2004; 15(4): 607-620.
50. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nature Reviews Genetics 2001; 2(6): 446-457.
51. Ghosh A, Ghosh S, Maiti GP. Association of FANCC and PTCH1 with the development of early dysplastic lesions of the head and neck. Annals of Surgical Oncology 2012; 19(Suppl 3): S528-S538.
52. Unno J, Itaya A, Taoka M. FANCD2 binds CtIP and regulates DNA-end resection during DNA interstrand crosslink repair. Cell Reports 2014; 7(4): 1039-1047.
53. Garner E, Smogorzewska A. Ubiquitylation and the Fanconi anemia pathway. Febs Letters 2011; 585(18): 2853-2860.
54. Meetei AR, de Winter JP, Medhurst AL. A novel ubiquitin ligase is deficient in Fanconi anemia. Nature Genetics 2003; 35(2): 165-170.
55. Han TJ, Lee CH, Yoo CW. Synchronous multifocal HPV-related neoplasm involving both the genital tract and the head-and-neck area: a case report of Fanconi anemia. Radiotherapy and Oncology 2009; 92(1): 138-141.
56. Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S. HPV-16 E7 reveals a link between DNA replication stress, Fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies. Cancer Research 2008; 68(23): 9954-9963.
57. Hussain S, Wilson JB, Medhurst AL. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Human Molecular Genetics 2004; 13(12): 1241-1248.
58. Wang X, Andreassen PR, D'Andrea AD. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Molecular and Cellular Biology 2004; 24(13): 5850-5862.
59. Hoskins EE, Morreale RJ, Werner SP. The Fanconi anemia pathway limits human papillomavirus replication. Journal of Virology 2012; 86(15): 8131-8138.
60. Knipscheer P, Räschle M, Smogorzewska A. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009; 326(5960): 1698-1701.
61. Rani R, Li J, Pang Q. Differential p53 engagement in response to oxidative and oncogenic stresses in Fanconi anemia mice. Cancer Research 2008; 68(23): 9693-9702.
62. Ceccaldi R, Parmar K, Mouly E. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 2012; 11(1): 36-49.
63. Rego MA, Harney JA, Mauro M, Shen M, Howlett NG. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor. Oncogene 2012; 31(3): 366-375.
64. Panneerselvam J, Pickering A, Zhang J. A hidden role of the inactivated FANCD2: upregulating DeltaNp63. Oncotarget 2013; 4(9): 1416-1426.
65. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. Journal of Clinical Investigation 2007; 117(5): 1370-1380.
66. Mighty KK, Laimins LA. p63 is necessary for the activation of human papillomavirus late viral functions upon epithelial differentiation. Journal of Virology 2011; 85(17): 8863-8869.
67. Chen J. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nature Clinical Practice. Gastroenterology & Hepatology 2008; 5(6): 306-307.
68. Chen J. Multiple signal pathways in obesity-associated cancer. Obesity Reviews 2011; 12(12): 1063-1070.
69. Wang X, Meyers C, Guo M, Zheng ZM. Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. International Journal of Cancer 2011; 129(6): 1362-1372.
70. Zheng ZM, Wang X. Regulation of cellular miRNA expression by human papillomaviruses. Biochimica et Biophysica Acta 2011; 1809(11-12): 668-677.
71. Zheng ZM. Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. International Journal of Biological Sciences 2010; 6(7): 730-755.
72. Chen J, McMillan N, Gu W. Intra-tumor injection of lentiviral-vector delivered shRNA targeting human papillomavirus E6 and E7 oncogenes reduces tumor growth in a xenograft cervical cancer model in mice. Journal of Solid Tumors 2012; 2(4): p4.
73. Chlon TM, Hoskins EE, Mayhew CN. High-risk human papillomavirus E6 protein promotes reprogramming of Fanconi anemia patient cells through repression of p53 but does not allow for sustained growth of induced pluripotent stem cells. Journal of Virology 2014; 88(19): 11315-11326.
74. Thomas MK, Pitot HC, Liem A, Lambert PF. Dominant role of HPV16 E7 in anal carcinogenesis. Virology 2011; 421(2): 114-118.
75. Shin MK, Sage J, Lambert PF. Inactivating all three rb family pocket proteins is insufficient to initiate cervical cancer. Cancer Research 2012; 72(20): 5418-5427.
76. Chung SH, Wiedmeyer K, Shai A, Korach KS, Lambert PF. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Research 2008; 68(23): 9928-9934.
77. Shin MK, Sage J, Lambert PF. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Research 2009; 69(14): 5656-5663.
78. Cortes-Malagon EM, Bonilla-Delgado J, Diaz-Chavez J. Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology 2013; 447(1-2): 155-165.
79. Jabbar SF, Abrams L, Glick A, Lambert PF. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Research 2009; 69(10): 4407-4414.
80. Michael S, Lambert PF, Strati K. The HPV16 oncogenes cause aberrant stem cell mobilization. Virology 2013; 443(2): 218-225.
81. Jones DL, Thompson DA, Munger K. Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. Virology 1997; 239(1): 97-107.
82. Funk JO, Waga S, Harry JB, Espling E, Stillman B. Galloway DA. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes and Development 1997; 11(16): 2090-2100.
83. Park JW, Nickel KP, Torres AD, Lee D, Lambert PF, Kimple RJ. Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. Radiotherapy and Oncology 2014; 113(3): 337-344.
84. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. Journal of Virology 2010; 84(10): 5212-5221.
85. Spardy N, Duensing A, Charles D. The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells. Journal of Virology 2007; 81(23): 13265-13270.